Telix Pharmaceuticals Limited and Amphastar Pharmaceuticals, Inc.: A Comprehensive Revenue Analysis

Pharma Giants: Revenue Growth Showdown

__timestampAmphastar Pharmaceuticals, Inc.Telix Pharmaceuticals Limited
Wednesday, January 1, 201421046100028336824
Thursday, January 1, 201525151900032319194
Friday, January 1, 201625516500029404631
Sunday, January 1, 201724017500031769230
Monday, January 1, 201829466600020439380
Tuesday, January 1, 201932235700024186536
Wednesday, January 1, 20203498460004680000
Friday, January 1, 20214377680004898000
Saturday, January 1, 2022498987000155984000
Sunday, January 1, 2023644395000496659000
Loading chart...

Unlocking the unknown

A Decade of Growth: Telix vs. Amphastar

In the ever-evolving pharmaceutical industry, revenue growth is a key indicator of success. Over the past decade, Amphastar Pharmaceuticals, Inc. has demonstrated a robust upward trajectory, with revenue increasing by over 200% from 2014 to 2023. This growth is highlighted by a significant leap in 2023, where revenue reached its peak, marking a 29% increase from the previous year.

Meanwhile, Telix Pharmaceuticals Limited, a relatively newer player, has shown remarkable progress. Despite a modest start, Telix's revenue surged dramatically in 2022, growing by over 3,000% compared to 2020. This meteoric rise underscores Telix's potential in the competitive landscape.

Both companies exemplify the dynamic nature of the pharmaceutical sector, where innovation and strategic positioning can lead to substantial financial gains. As we look to the future, these trends offer a glimpse into the potential trajectories of these industry players.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025